Gapping Up:
Earnings/guidance: LEN +2.3%
M&A: XGTI +25.2% (signs final definitive business purchase agreement to acquire Vislink Communication Systems)
Other news: TNXP +41.3% ( announces that the FDA has granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD)), GSAT +28% (reports the FCC has put the company's revised proposal on circulation), BCLI +12.4% (reports on End-of-Phase 2 Meeting w/ the FDA; the FDA has accepted the key elements of the Phase 3 program to support a BLA for NurOwn in ALS), ACHN +7.7% (ticking higher, still checking for anything).
Other news: TNXP +41.3% ( announces that the FDA has granted Breakthrough Therapy designation to TNX-102 SL for the treatment of posttraumatic stress disorder (PTSD)), GSAT +28% (reports the FCC has put the company's revised proposal on circulation), BCLI +12.4% (reports on End-of-Phase 2 Meeting w/ the FDA; the FDA has accepted the key elements of the Phase 3 program to support a BLA for NurOwn in ALS), ACHN +7.7% (ticking higher, still checking for anything).
Analyst actions: CRI +3.9% (upgraded to Buy from Neutral at Citigroup), ASML +1.5% (upgraded to Buy from Neutral at BofA/Merrill).